Caravelle International Group Announces Receipt of Nasdaq Deficiency Notice
The Notice has no immediate impact on the listing of the Company's securities, which will continue to trade on Nasdaq, subject to the Company's compliance with the other continued listing requirements of Nasdaq. Under the Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Notice to submit a plan of compliance to Nasdaq. If Nasdaq accepts the plan, they can grant the Company an exception of up to 180 calendar days from the original due date of the Form 20-F, or until
Caravelle International Group is fully committed to satisfying all of NASDAQ's listing requirements. The company has implemented a comprehensive plan to enhance its internal reporting processes and is working closely with its auditors and legal advisors to ensure the timely and accurate submission of all necessary documents.
About Caravelle International Group
Caravelle is a global ocean technology company. Its business comprises of two sectors: the traditional business in international shipping, operated by the Topsheen Companies (Topsheen Shipping Group Corporation (
Forward Looking Statements
This announcement contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the "safe harbor" provisions of the
View original content to download multimedia:https://www.prnewswire.com/news-releases/caravelle-international-group-announces-receipt-of-nasdaq-deficiency-notice-302103562.html
SOURCE Caravelle International Group
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Purina and Mariska Hargitay Bring the Purple Leash Project to U.S. Soccer, Launch Limited-Edition Scarves Supporting Abuse Survivors and Pets
- Cutaneous Lupus Erythematosus Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share